Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease

Cytokine

Volumn 49, Issue 2, 2010, Pages 163-170

  Deeva, Irina ^a   Mariani, Serena ^a   De Luca, Chiara ^a   Pacifico, Valeria ^a   Leoni, Luca ^a   Raskovic, Desanka ^a   Kharaeva, Zaira ^b   Korkina, Liudmila ^a   Pastore, Saveria ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b KABARDINO BALKARIAN STATE UNIVERSITY   (Russian Federation)

Author keywords

Chemokine; Cytokine; Growth factor; Psoriasis

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PSORIASIS; SKIN;

EID: 73649093378     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.09.014     Document Type: Article

References (46)

1. Griffiths C.E.M., and Barker J.W.N. Pathogenesis and clinical features of psoriasis. Lancet 370 (2007) 263-271
2. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128 (2008) 1207-1211
3. Nestle F.O., Kaplan D.H., and Barker J. Psoriasis. New Engl J Med 361 (2009) 496-509
4. Myers W.A., Gottlieb A.B., and Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24 (2006) 438-447
5. Henseler T., and Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 47 (2008) 1019-1023
6. Schmitt J., and Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210 (2005) 194-199
7. De Vlam K., Gottlieb A.B., and Fitzgerald O. Biological biomarkers in psoriatic disease. J Rheumatol 35 (2008) 1443-1448
8. Elkayam O., Yaron I., Shirazi I., Yaron M., and Caspi D. Serum levels of IL-10, IL-6, IL-1ra and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19 (2000) 101-105
9. Mastroianni A., Minutilli E., Mussi A., Bordignon V., Trento E., D'Agosto G., et al. Cytokine profiles during infliximab monotherapy in psoriasis arthritis. Br J Dermatol 153 (2005) 531-536
10. Zalewska A, Glowacka E, Wyczolkowka J, Tchòrzewski H, Narbutt J, Sysa-Jedrzejowska A. Interleukin 6 and 8 levels in plasma and fibroblasts cultures in psoriasis. Mediators Inflamm 2006, ID 81767.
11. Giustizieri M.L., Mascia F., Frezzolini A., De Pità O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
12. Bigler C.F., Norris D.A., Weston W.L., and Arend W.P. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol 98 (1992) 38-44
13. Li W., Fan J., Chen M., Guan S., Sawcer D., Bokoch G.M., et al. Mechanism of human dermal fibroblast migration driven by type I collagen and platelet-derived growth factor BB. Mol Biol Cell 15 (2004) 294-309
14. Heldin C.H., and Westermarck B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283-1316
15. Krane J.F., Murphy D.P., Gottlieb A.B., Carter D.M., Hart C.E., and Krueger J.G. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J Invest Dermatol 96 (1991) 983-986
16. Ansel J.C., Tiesman J.P., Olerud J.E., Krueger J.G., Krane J.F., Tara D.C., et al. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 92 (1993) 671-678
17. Espinoza L.R., Espinoza C.G., Cuellar M.L., Scopelitis E., Silveira L.H., and Grotendorst G.R. Fibroblast function in psoriasi arthritis. II. Increased expression of beta platelet derived growth factor receptors and increate production of growth factor and cytokines. J Rheumatol 21 (1994) 1507-1511
18. Jacob S.E., Nassiri M., Kerdel F.A., and Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 12 (2003) 309-313
19. Arican O., Aral M., Sasmaz S., and Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 5 (2005) 273-279
20. Menter A., Gottlieb A., Feldman S.R., Van Voorhees A.S., Leonardi C.L., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 (2008) 826-850
21. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 159 Suppl. 2 (2008) 2-9
22. Gottlieb A.B., Dann F., and Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 7 (2008) 563-572
23. National Institute of Health, Third report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults [Adult Panel Treatment Panel III]. Executive summary. NIH Pubbl No. 01-3670, Bethesda, MD: National Institute of Health, National Heart, Lung, and Blood Institute; 2001.
24. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
25. Gear A.R., and Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 10 (2003) 335-350
26. Ayache S., Panelli M.C., Byrne K.M., Slezak S., Leitman S.F., Marincola F.M., et al. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. J Translat Med 4 (2006) 40-56
27. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171 (2003) 3262-3269
28. Boniface K., Lecron J.C., Bernard F.X., Dagregorio G., Guillet G., Nau F., et al. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis of psoriasis. Eur Cytokine Netw 16 (2005) 309-319
29. Döcke W.D., Asadullah K., Belbe G., Ebeling M., Höflich C., Friedrich M., et al. Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J Leukoc Biol 85 (2009) 582-593
30. Hammerberg C., Arend W.P., Fisher G.J., Chan L.S., Berger A.E., and Haskill J.S. Interleukin-1 receptor antagonist in normal and psoriatic skin. J Clin Invest 90 (1992) 571-583
31. Debets R., Hegmans J.P., Troost R.J., Benner R., and Prens E.P. Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. Eur J Immunol 25 (1995) 1624-1630
32. Prens E.P., Benne K., van Damme J., Bakkus M., Brakel K., Benner R., et al. Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol 95 (1990) 121S-124S
33. Ohta Y., Katayama I., Funato T., Yokozeki H., Nishiyama S., Hirano T., et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res 283 (1991) 351-356
34. Nickoloff B.J., Karabin G.D., Barker J.N., Griffiths C.E., Sarma V., Mitra R.S., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138 (1991) 129-140
35. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
36. Szabo S.K., Hammerberg C., Yoshida Y., Bata-Csorgo Z., and Cooper K.D. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 111 (1998) 1072-1078
37. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suàrez-Fariñas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159 (2008) 1092-1102
38. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 (2004) 125-130
39. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176 (2006) 1908-1915
40. Fitch E., Harper E., Skorcheva I., Kurtz S.E., and Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9 (2007) 461-467
41. Deleuran M., Buhl L., Ellingsen T., Harada A., Larsen C.G., Matsushima K., et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. J Dermatol Sci 13 (1996) 228-236
42. Raychaudhuri S.P., Jiang W.Y., Farber E.M., Schall T.J., Ruff M.R., and Pert C.B. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79 (1999) 9-11
43. Gottlieb A.B., Luster A.D., Posnett D.N., and Carter D.M. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 168 (1988) 941-948
44. Schön M.P., and Boehncke W.H. Psoriasis. New Engl J Med 352 (2005) 1899-1912
45. Zheng Y., Niyonsaba F., Ushio H., Ikeda S., Nagaoka I., Okumura K., et al. Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation. Immunology 124 (2008) 357-367
46. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.